Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tolerability

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14,030 result(s) found for: Tolerability. Displaying page 3 of 702.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2021-000454-26 Sponsor Protocol Number: 76702 Start Date*: 2021-03-25
    Sponsor Name:Leiden University Medical Center
    Full Title: Establishing the safety, tolerability and immunogenicity of intradermal delivery of mRNA SARS-CoV-2 vaccine in healthy adults
    Medical condition: Healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001845-40 Sponsor Protocol Number: R092670-PSY-3005 Start Date*: 2005-08-24
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Crossover Study to Evaluate the Overall Safety and Tolerability of Paliperidone Palmitate Injected in the Deltoid or Gluteus Muscle in Subjects With Schizophrenia
    Medical condition: Schizophrenia according to DSM-IV-TM [disorganized type (295.10), catatonic type (295.20), paranoid type (295.30), residual type (295.60) or undifferentiated type (295.90)]
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2023-000946-41 Sponsor Protocol Number: VX19-809-124 Start Date*: 2023-10-17
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 3, Open-label, and Rollover Study to Evaluate the Long-term Safety and Tolerability of Lumacaftor/Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 ...
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-003536-12 Sponsor Protocol Number: CIGE025B1301E1 Start Date*: 2016-02-16
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: An Extension Study to CIGE025B1301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite...
    Medical condition: Allergic Asthma
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-001781-41 Sponsor Protocol Number: NVALT1asbestosis Start Date*: 2019-03-07
    Sponsor Name:Nederlandse Vereniging van Artsen voor longziekten en Tuberculose
    Full Title: Evaluation of safety and tolerability of pirfenidone in asbestosis, a multicenter study
    Medical condition: asbestosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-005014-21 Sponsor Protocol Number: DPI-tobra-kind Start Date*: Information not available in EudraCT
    Sponsor Name:University Medical Center Groningen
    Full Title: Pharmacokinetic evaluation and tolerability of dry powder tobramycin via the Cyclops® in children with cystic fibrosis
    Medical condition: Cystic Fibrosis Lung infections
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003192-30 Sponsor Protocol Number: CLJN452X2202 Start Date*: 2016-03-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double blind, randomized placebo controlled crossover multiple dose study of LJN452 to assess safety, tolerability and efficacy in patients with primary bile acid diarrhea (pBAD).
    Medical condition: primary bile acid diarrhea
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10032786 Other specified intestinal malabsorption LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001764-21 Sponsor Protocol Number: MANS11 Start Date*: 2011-05-19
    Sponsor Name:Magle AB
    Full Title: The effect of 6 weeks’ use of the Nicachet 4 mg nicotine powder in pouch on the oral mucosa. A short-term smoking cessation and tolerability study.
    Medical condition: Nicotine addiction
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10053325 Smoking cessation therapy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001049-15 Sponsor Protocol Number: HD-TREX Start Date*: 2018-08-24
    Sponsor Name:ANOVA (Andrologi, Sexualmedicin, Transmedicin) Karolinska Universitetssjukhuset och Umeå Universitet
    Full Title: Pharmacological treatment of hypersexual disorder; an open pilot study to evaluate the feasibility and effectiveness of treatment with Naltrexone
    Medical condition: Hypersexual disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10066364 Hypersexuality PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003321-14 Sponsor Protocol Number: TS002 Start Date*: 2019-11-01
    Sponsor Name:Tesla Medical s.r.o.
    Full Title: 12-weeks, Open-label, Randomized, Multicenter, Post Marketing Clinical Follow-up Study to Evaluate Safety, Tolerability and Efficacy of the Home-Based electrical Transcutaneous NeuroModulation (eT...
    Medical condition: Naive Subjects With Overactive Bladder (OAB)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001069-20 Sponsor Protocol Number: HIDROGUM21 Start Date*: 2022-01-12
    Sponsor Name:Vall d'Hebron Hospital Universitari
    Full Title: Tolerability and acceptance of two oral hydrocortisone compounding formulation for pediatrics
    Medical condition: Adrenal hyperplasia or isolated primary adrenal insufficiency or panhypopituitarism (secondary or tertiary adrenal insufficiency)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000465-17 Sponsor Protocol Number: CHL.3-02-2019 Start Date*: 2020-06-16
    Sponsor Name:Sintetica S.A.
    Full Title: A Phase II/III, Randomized, Double-Masked, Vehicle-Controlled, Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in healthy volunteers
    Medical condition: healthy volunteers
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10024758 Local anaesthesia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002934-57 Sponsor Protocol Number: PS0018 Start Date*: 2017-02-22
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A multicenter, 48-week, open-label extension study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis.
    Medical condition: Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001727-12 Sponsor Protocol Number: TPV11 Start Date*: 2019-10-24
    Sponsor Name:Topas Therapeutics GmbH
    Full Title: A multi-centre, open-label, phase 1 study, Part A single ascending dose and Part B multiple dose, to evaluate the safety, tolerability and pharmacokinetics, and to explore early signs of effectiven...
    Medical condition: Pemphigus vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005919-24 Sponsor Protocol Number: C/399/2002 Start Date*: 2006-07-19
    Sponsor Name:Dr. Falk Pharma Portugal
    Full Title: Randomized, multicenter, double blind, placebo controlled trial, for the evaluation of the efficacy and tolerability of ursodeoxycholic acid on the dissolution of cholesterol gallstones (<15mm) aft...
    Medical condition: Randomized multicenter double blind, placebo controlled trial, for the evaluation of the efficacy and tolerability of UDCA on the dissolution of cholesterol gallstones (<15mm) after 18 months of th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003186-18 Sponsor Protocol Number: LOWOL-19 Start Date*: 2020-02-05
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: EFICACY AND TOLERABILITY OF TWO REDUCED VOLUME PRODUCTS FOR COLORRECTAL CANCER SCREENING COLONOSCOPY: A COMPARATIVE, PARALLEL RANDOMIZED CLINICAL TRIAL. LOWOL STUDY.
    Medical condition: compare the adenoma detection rate between the two products
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014522-41 Sponsor Protocol Number: GT-22 Start Date*: 2010-01-26
    Sponsor Name:ALK-Abelló A/S
    Full Title: An interventional trial assessing the tolerability and safety of GRAZAX® in adults with grass pollen allergy
    Medical condition: Grass pollen induced rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2010-019249-25 Sponsor Protocol Number: 981 Start Date*: 2010-08-12
    Sponsor Name:Biotest AG
    Full Title: An open, prospective trial investigating pharmacokinetics and safety (Part A) of the human normal immunoglobulin for intravenous infusion (IVIG) BT090 and tolerability and safety of escalating infu...
    Medical condition: Primary immunodeficiency disease (PID)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10010509 Congenital hypogammaglobulinemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2004-000687-27 Sponsor Protocol Number: CLIC477D2303E01 Start Date*: 2004-11-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A 52 week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2500 mg/d in the treatment of manic episodes of bipolar I disorder
    Medical condition: Bipolar I disorder, manic and mixed episodes DSM-IV criteria 296.0, 296.4 or 296.6
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: AT (Prematurely Ended) SK (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-003320-40 Sponsor Protocol Number: EP-003 Start Date*: 2023-03-14
    Sponsor Name:Empros Pharma AB
    Full Title: A 26-week, double-blind, randomized study in participants with overweight or obesity investigating the added contribution of acarbose in EMP16 on efficacy, safety and tolerability
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 09:52:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA